A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Trial Profile

A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms IMvigor 210; IMvigor210
  • Sponsors Roche
  • Most Recent Events

    • 21 Jul 2017 According to a Roche media release, the CHMP adopted a positive opinion for the use of TECENTRIQ as a monotherapy. This positive opinion is based on results from the IMvigor211 study and cohorts 1 and 2 of the IMvigor210 study.
    • 20 Apr 2017 According to a NYU Langone Medical Center media release, Arjun V. Balar an assistant professor at NYU Langone's Perlmutter Cancer Center is the lead investigator of this trial.
    • 18 Apr 2017 According to a Roche Canada media release, based on the data from this trial, Health Canada has approved with conditions TECENTRIQ™ (atezolizumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top